BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 9816253)

  • 21. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
    Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
    Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic accuracy and safety of 16α-[
    Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
    Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
    He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
    PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
    Evangelista L; Guarneri V; Conte PF
    Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[
    Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
    J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer.
    Ulaner GA
    Semin Nucl Med; 2022 Sep; 52(5):574-583. PubMed ID: 35379454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
    Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
    Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes.
    Jonson SD; Bonasera TA; Dehdashti F; Cristel ME; Katzenellenbogen JA; Welch MJ
    Nucl Med Biol; 1999 Jan; 26(1):123-30. PubMed ID: 10096512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
    Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
    J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study.
    Inoue T; Kim EE; Wallace S; Yang DJ; Wong FC; Bassa P; Cherif A; Delpassand E; Buzdar A; Podoloff DA
    Cancer Biother Radiopharm; 1996 Aug; 11(4):235-45. PubMed ID: 10851543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
    Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
    J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer.
    Katzenellenbogen JA; Welch MJ; Dehdashti F
    Anticancer Res; 1997; 17(3B):1573-6. PubMed ID: 9179196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
    Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
    Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Validity of 16α-[
    van Geel JJL; Boers J; Elias SG; Glaudemans AWJM; de Vries EFJ; Hospers GAP; van Kruchten M; Kuip EJM; Jager A; Menke-van der Houven van Oordt WC; van der Vegt B; de Vries EGE; Schröder CP;
    J Clin Oncol; 2022 Nov; 40(31):3642-3652. PubMed ID: 35584346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.
    Boers J; Schröder CP; Hospers GAP; de Vries EFJ; Glaudemans AWJM
    Clin Nucl Med; 2021 Mar; 46(3):e165-e167. PubMed ID: 33181752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2-[18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers.
    Yadav D; Kumar R; Phulia A; Basu S; Alavi A
    PET Clin; 2022 Jul; 17(3):399-413. PubMed ID: 35717099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.